升麻属植物传统用途、化学成分、药理与毒理学综述
本文系统综述升麻属植物在民族医学中的传统用途、植物学特征、化学成分、质量控制、药理及毒理研究,时间跨度1953至2017年。该属主要活性成分为三萜皂苷,7种植物已鉴定超457种化合物,具有更年期综合征、抗骨质疏松、抗病毒、抗肿瘤、抗氧化及抗血管生成等活性,但同时报告了肝、心血管及神经毒性。作者强调质量控制与安全性评估仍不完善,仅少部分植物允许药用,需深入研究后方可临床推广。
要点
- 升麻属传统用于风热头痛、牙痛、口疮、咽痛、麻疹、子宫脱垂等,并作膳食补充剂预防更年期症状和骨质疏松。
- 主要活性成分为三萜皂苷,7种升麻属植物已鉴定超过457种化合物。
- 药理研究证实提取物及纯化合物有更年期综合征、抗骨质疏松、抗病毒、抗肿瘤、抗氧化和抗血管生成活性。
核心结论
- 现代药理学研究验证了升麻属多种传统用途,但质量控制与安全性评估仍不完整。
- 目前仅少部分升麻属植物允许药用,亟需扩展药用资源并深入研究方可临床推广。
- 研究主要集中于三萜皂苷,其他类型化合物可能具有新生物活性但缺乏系统研究。
研究设计与样本
- 综述检索科学数据库(Google Scholar、PubMed、SciFinder Scholar、Science Direct、CNKI、Baidu Scholar、Web of Science、China Knowledge Resource Integrated Database)、中草药经典、民族植物学书籍、学位论文、中国药典及同行评议期刊等。
- 文献引用时间范围为1953年至2017年,并使用The Plant List验证学名与异名。
主要发现
- 升麻属主要化学成分为三萜皂苷、苯丙素类、含氮化合物、色酮类、黄酮类和4α-甲基甾体,主要活性成分被认为存在于三萜皂苷部位。
- 对7种升麻属植物的研究已鉴定超过457种化合物。
- 粗提物及某些纯化合物显示更年期综合征治疗、抗骨质疏松、抗病毒、抗肿瘤、抗氧化和抗血管生成活性。
- 已报告升麻属植物诱导的肝、心血管、中枢及周围神经系统毒性。
关键数值与推荐
- 7种升麻属植物已鉴定超过457种化合物。
- 文献引用时间范围为1953年至2017年。
- 原文未报告具体阈值、剂量、样本量或P值。
临床怎么用
- 临床使用升麻属药物时应高度关注肝、心血管及神经系统毒性风险。
- 仅少部分升麻属植物允许药用,应严格遵循法定药用品种范围。
- 在早期开发与临床试验阶段应将安全性考虑置于高优先级。
局限性
- 升麻属植物的质量控制与安全评估仍不完整。
- 仅少部分升麻属植物允许作为药物使用,药用资源扩展 urgently needed。
- 研究主要集中于三萜皂苷,其他类型化合物的系统研究缺乏。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Plants of the genus Cimicifuga have long been used as an ethnomedicine in China, Europe, and North America for its high medicinal value and health benefits. Their dried rhizomes are widely used for treating wind-heat headache, toothache, aphtha, sore throat, measles, spot poison, archoptosis, and uterine prolapse. In addition, it is used as a dietary supplement for preventing women menopausal symptoms and osteoporosis. AIM OF THE REVIEW: This paper aims to provide up-to-date information on the genus Cimicifuga, including botanical characterization, medicinal resources, traditional medicinal uses, phytochemistry, quality control, pharmacological research as well as the toxicology. The possible structural-activity relationships and molecular mechanisms of the bioactive constituents are discussed in ways that contribute to the structural optimization and preclinical safety assessment for further drug design. MATERIALS AND METHODS: The relevant information on Cimicifuga was collected from scientific databases (such as Google Scholar, PubMed, SciFinder Scholar, Science Direct, CNKI, Baidu Scholar, Web of Science, China Knowledge Resource Integrated Database), Chinese herbal classics, ethnobotanical books, PhD and MSc dissertations, Chinese Pharmacopoeia, published articles in peer-reviewed journals, local magazines, and unpublished materials. In addition, the Plant List (TPL, www.theplantlist.org) was also used to validate the scientific names and synonyms of this plant. The literature cited in this review dated from 1953 to 2017. RESULTS: The majority of chemical constituents of this plant include triterpenoid glycosides, phenylpropanoids, nitrogenous compounds, chromones, flavonoids and 4α-methyl steroid. Among them, the primary bioactive constituents are believed to be present in the triterpene glycoside fraction. To date, investigation of seven Cimicifuga spp. plants led to the identification of more than 457 compounds. Years of pharmacological research proved that the crude extracts and certain pure compounds obtained from Cimicifuga exhibited menopausal syndrome-treatment, anti-osteoporosis, antiviral, antitumor, antioxidant and antiangiogenic activities. On the other hand, Cimicifuga plant-induced toxicities of liver, cardiovascular, central and peripheral nervous systems have also been reported. Therefore, safety consideration should be placed into a high priority for herbal medicine Cimicifuga therapy in the early stages of development and clinical trials. CONCLUSIONS: This review presents information on botany, medicinal resources, and traditional medicinal history of some Cimicifuga plants. Modern pharmacology researchers have validated many traditional uses of Cimicifuga species. As the quality control and safety assessment of Cimicifuga plants is still incomplete, only a small part of the plant is permitted to be used as medicines. Expansion of medicinal resources in Cimicifuga is urgently needed to enable its full use. Currently research primarily focuses on the triterpenoid glycosides but there are many other types of compounds which may possess new biological activities however the systematic studies of these compounds are lacking. Extensive study is required on Cimicifuga plant before it can be fully used in clinics as a potent drug candidate.
引用
- Guo Y, Yin T, Wang X, et al. Traditional uses, phytochemistry, pharmacology and toxicology of the genus Cimicifuga: A review. J Ethnopharmacol. 2017. PMID: 28826891. doi:10.1016/j.jep.2017.07.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。